Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Respiratory

Set Alert for Respiratory

Avalyn Raises $175m To Fund Inhaled Versions Of Pulmonary Fibrosis Drugs

Financing Snapshot: Seattle biotech claims its targeted, inhalable versions of Esbriet and Ofev, both oral IPF drugs, may offer better tolerability and stronger efficacy than established products.

Financing Business Strategies

The Game Looks Up For Galecto

The Boston-based biotech is weighing up its options as the fall-out from its failed IPF candidate casts a shadow over Galecto’s future.

Restructuring Business Strategies

What Verona Needs To Make COPD Drug Ensifentrine A Success

Getting on the best reimbursement pathway in the US will be vital for the UK company as it moves closer to approval and taking on the established players in the chronic obstructive pulmonary disease arena.

Respiratory Business Strategies

Moderna Shows Ambition With Flu Success And Cancer Therapy Expansion

Slower COVID-19 vaccine sales will see Moderna’s revenues decline this year, but the company is investing heavily to speed a new wave of therapies to the market.

Cancer Infectious Diseases

AstraZeneca Looks To Challenge GSK’s Nucala With Fasenra EGPA Data

AstraZeneca's Fasenra has demonstrated non-inferiority compared with GSK's fellow interleukin-5 inhibitor Nucala for eosinophilic granulomatosis with polyangiitis and the company hopes its more convenient single monthly subcutaneous injection will win market share if approved for the rare, immune-mediated inflammatory disease.

Respiratory Clinical Trials

Bristol Myers Squibb Gets A Second Hit In Pulmonary Fibrosis

Phase III trials of BMS-986278 are already being prepped. 

Clinical Trials Respiratory

Insmed Makes A Case For Accelerated Approval Of First-Line Arikayce Use

Insmed’s ARISE trial validated a patient-reported outcome measure it plans to use as the new primary endpoint in the ongoing pivotal ENCORE study, but it will ask the US FDA about accelerated approval based on ARISE. 

Clinical Trials Growth

Asthma And RSV Will Be Hot Topics At ERS 2023

Elsewhere at the European Respiratory Society meeting, Bristol Myers Squibb will hope that its LPA1 antagonist can add a hit in progressive pulmonary fibrosis to the success it has already posted in the idiopathic form of the disease. 

Clinical Trials Respiratory

Rise In COVID-19 Numbers Won’t Solve Moderna’s Slump

Moderna is suffering from a slump in sales of its COVID-19 vaccine, and investors remain skeptical about its chances of hitting anywhere near those blockbuster heights with its next wave of products.

Respiratory Oncology

Another IPF Drug Failure As Galecto Therapy Suffers Mid-Stage Flop

Galecto’s decision to discontinue its idiopathic pulmonary fibrosis candidate after disappointing Phase IIb results represents the latest in a number of mid/late-stage failures to treat the disease.

Clinical Trials Respiratory

'Evergreen' Cipla: Chair Hamied Talks New Technologies Amid 'Speculative' Sale News

Cipla’s chief Dr Yusuf Hamied talks about investments in new technologies that will shape the company’s future, terming reports of a stake sale as “speculative" but not going as far as an outright denial.

Commercial Respiratory

Cipla Rides High Amid US Market Shakeout

Cipla reports highest ever quarterly revenues in the US, a market that’s seeing lower “price compression” amid sell-offs, bankruptcies and a rebalancing of the supply chain. The firm’s portfolio has a “lot of steam” left to be unlocked and it’s also keeping an eye on the impact of the tornado-hit Pfizer site on supplies.

Commercial India

GSK Confirms Arexvy Price And US Contract Negotiations Ahead Of Launch

GSK is gearing up for its most important new product launch in years and hopes US payers will buy into Arexvy’s likely higher price than Pfizer’s rival RSV vaccine.

Cancer Infectious Diseases

Pieris Looks For Way Out After AstraZeneca Exits Respiratory Collaboration

The US biotech is hoping to either partner off its wholly owned pipeline or become a target for an acquisition or merger after AstraZeneca’s asthma exit left it with dwindling cash, and a need to cut costs.

Companies Business Strategies

Kinaset Advances Inhaled Pan-JAK Inhibitor For Broad Use In Severe Asthma

Emerging Company Profile: The US biotech acquired its sole asset from CDMO Vectura in 2020 and is now gearing up for a Phase II proof-of-concept trial in severe asthma to help address the unmet need in non-eosinophilic patients.

Emerging Company Profile Companies

Sanofi Defends Beyfortus Amid Emerging Maternal RSV Vaccine Threat

The French firm used a vaccines investor event to tout its respiratory syncytial virus prophylactic, Beyfortus, citing real-world data as well as a predictive model following recent questions about its utility in the face of advancing maternal vaccines.

Companies Vaccines
See All
UsernamePublicRestriction

Register